Ad26.COV2·S加强针接种前后抗体水平可预测COVID-19疾病风险
研究在美国开展,部分实施期与SARS-CoV-2奥密克戎BA.1变异株出现重叠,受试者在完成单剂Ad26.COV2·S或两剂BNT162b2基础免疫至少6个月后接种Ad26.COV2·S加强针。加强后第15天武汉株结合抗体、中和抗体及奥密克戎BA.1交叉中和抗体滴度越高,有症状COVID-19风险越低,且不受基础免疫方案影响;第1天武汉参考株中和抗体水平与有症状COVID-19风险呈统计学显著负相关。
要点
- 加强后第15天结合抗体、中和抗体及BA.1交叉中和抗体滴度越高,有症状COVID-19风险越低。
- 该关联不受基础免疫为单剂Ad26.COV2·S或两剂BNT162b2的影响。
- 第1天武汉参考株中和抗体水平与有症状COVID-19风险呈统计学显著负相关。
核心结论
- 加强后第15天结合抗体、中和抗体及奥密克戎BA.1交叉中和抗体滴度较高与有症状COVID-19风险较低一致相关,且不受基础免疫方案影响。
- 第1天针对武汉参考株的中和抗体水平与有症状COVID-19风险呈统计学显著负相关。
- 这些发现凸显了评估疫苗加强针免疫相关指标的价值,尤其是在新发SARS-CoV-2变异株背景下。
研究设计与样本
- 疫苗试验在美国开展,大部分研究实施期与SARS-CoV-2奥密克戎BA.1变异株出现重叠。
- 受试者在完成单剂Ad26.COV2·S或两剂BNT162b2基础免疫至少6个月后接种Ad26.COV2·S加强针。
- 在第1天(加强前)、加强后第15天及加强后6个月评估武汉株结合抗体、中和抗体及奥密克戎BA.1交叉中和抗体。
- 临床试验注册号:NCT04999111。
主要发现
- 加强后第15天结合抗体、中和抗体及BA.1交叉中和抗体滴度较高与有症状COVID-19风险较低一致相关,且不受基础免疫方案影响。
- 多变量分析得到相似结果。
- 第1天针对武汉参考株的中和抗体水平与有症状COVID-19风险呈统计学显著负相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Identifying immune correlates of risk following COVID-19 vaccine boosters has become paramount as a result of the challenges in generating additional efficacy data. The trial data described here was collected in the United States, with a large part of the study conduct coinciding with the emergence of the SARS-CoV-2 Omicron BA.1 variant. The vaccine trial involved the administration of a booster dose of Ad26.COV2·S at least 6 months after primary vaccination with either a single dose of Ad26.COV2·S or a 2-dose BNT162b2 vaccine regimen. Immunogenicity was assessed through Wuhan Spike binding antibodies (bAb), neutralizing antibodies (nAb), and Omicron BA.1 cross-neutralizing antibodies (nAb BA.1) at Day 1 (pre-boost), Day 15-, and 6-months post-boost. Immune correlates analyses demonstrate that, higher titers of bAb, nAb, and nAb BA.1 at Day 15 were consistently associated with a lower risk of symptomatic COVID-19 following a booster dose of Ad26.COV2·S, irrespective of the primary vaccine regimen. Similar results were obtained using multivariable analyses. Furthermore, Day 1 nAb levels against the Wuhan reference strain exhibited a statistically significant inverse relationship with the risk of symptomatic COVID-19. These findings highlight the value of assessing immune correlates for vaccine boosters, especially in the context of emerging SARS-CoV-2 variants. Clinical trials registration:NCT04999111.
引用
- Roels S, Bruckner M, Sadoff J, et al. Pre- and post-Ad26.COV2·S booster dose antibody levels predict COVID-19 disease risk. Vaccine. 2024. PMID: 39121698. doi:10.1016/j.vaccine.2024.126159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。